BMS-Pfizer Alliance Working to Understand Gaps in Atrial Fibrillation (AFib) Detection and Diagnosis
Atrial fibrillation (AFib) is a known risk factor for stroke, however, approximately 1 of 3 patients remain undiagnosed. Pfizer and BMS believe that raising public awareness of AFib and its link to stroke and convening the advocacy community are critical for tackling this health issue. Together with leading experts in the community, Pfizer and BMS are working to help identify gaps in detection and diagnosis of AFib in appropriate high risk patients through multi-stakeholder programs, such as the "Matter of Moments" thought leadership initiative in the U.S. and the 2018 European Summit on Inequalities in AF Care.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families